Liver Cancer
Conditions
Interventions
TACE+Lenvatinib:Lenvatinib
TACE+Sorafenib:Sorafenib
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
23 Years to 72 Years
Inclusion criteria
Inclusion criteria: 1. Patients with primary or recurrent HCC who strictly comply with the clinical diagnostic criteria of the code for the diagnosis and treatment of primary liver cancer (version 2019) or confirmed by histopathology or cytology, and who are unable to accept palliative surgery and do not reach the bclc-c level; 2. Did not receive any systemic treatment; 3. The level of child Pugh A / B; 4. According to mrecist1.1, there were measurable lesions; 5. Aged 18 to 75 years; 6. ECoG physical condition 0-1; 7. Total bilirubin 1500 / uL; 10. Platelet > 75000 / uL; 11. Serum uric acid =2.8 g/dl; 14. Prothrombin time (PT) - international normalized ratio (INR): PT < reference value + 6 seconds or INR < 1.7; 15. Subjects with active hepatitis B or C can receive antiviral drugs other than interferon.
Exclusion criteria
Exclusion criteria: 1. Severe infections requiring systemic antibiotic treatment occurred at enrollment or within 7 days before the first administration; 2. Pregnancy or lactation; 3. Poor compliance is expected; 4. Uncontrollable diseases include (but are not limited to): ongoing or active infection, symptomatic congestive heart failure (NYHA standard, grade III or IV), arrhythmia, and mental illness; 5. Subjects who had received any anti-cancer treatment before entering the study and did not return to baseline (except for alopecia) or 5% bone marrow area) within 4 weeks before participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate;Adverse events rate; | — |
Countries
China
Contacts
Public ContactBiao Yang
West China Hospital, Sichuan University
Outcome results
None listed